|
||||||||||||||||||||
Title: |
Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report | |||||||||||||||||||
| Authors: | Gary Levy, M.D., John Elkas, M.D., Alicia Y. Armstrong, M.D., and Lynnette K. Nieman, M.D. | |||||||||||||||||||
|
BACKGROUND: Prolonged exposure to a selective progesterone receptor modulator (ulipristal acetate) in a patient with benign metastasizing leiomyoma did not result in endometrial hyperplasia or neoplasia. CASE: A woman with history of benign metastasizing leiomyoma underwent medical treatment for 5 years with ulipristal acetate. Endometrial biopsies were performed at established intervals to monitor for intraepithelial neoplasia or progesterone receptor modulator–associated endometrial changes (PAECs). The patient tolerated UPA therapy well; there was no evidence of hyperplasia or proliferative changes associated with progesterone-associated endometrial changes. CONCLUSION: In this case prolonged exposure to ulipristal acetate did not result in premalignant or malignant endometrial pathology. |
||||||||||||||||||||
| Keywords: | contraceptive agents; Ella norpregnadiene; endometrial hyperplasia; Esmya; fibroid; fibroids, uterine; leiomyoma; progesterone receptor; selective progesterone receptor modulator; ulipristal acetate | |||||||||||||||||||
| Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from  |
||||||||||||||||||||
